Feasibility Inputs to Protocol: Turning Real-World Constraints into a Trial You Can Actually Run

Published on 16/11/2025

From Hypothesis to Field Reality: Building Feasible Protocols That Regulators and Sites Trust

Translating Early Feasibility into Protocol Reality: People, Places, and Practical Limits

Feasibility is the bridge between scientific ambition and operational truth. Before a single inclusion criterion is drafted, sponsors should test assumptions about who will enroll, where procedures can be delivered, and how real-world care interacts with trial requirements. In modern programs, feasibility is not a single survey—it’s a structured, quality-by-design exercise aligned with the ICH GCP framework (E6[R3], E8[R1]) and recognizable

to authorities such as the U.S. FDA, the European EMA, Japan’s PMDA, Australia’s TGA, and the public-health lens of the WHO.

Begin with the condition’s ground truth. Map the epidemiology and standard of care (SoC) by region and care setting (academic centers, community hospitals, specialty clinics). Feasibility interviews should probe diagnostic pathways (time to diagnosis, required imaging/biomarkers), waiting lists for key procedures, and the “real” patient flow. Translate those findings into protocol constraints: if definitive imaging is typically booked 4–6 weeks out, your Week-4 baseline MRI window is a risk; if biomarker results are returned in 10 business days, same-week randomization is unrealistic.

Recruitment sources and prescreening pathways. Identify which clinics, registries, and referral networks produce eligible patients. Test inclusion/exclusion criteria on historical cohorts (de-identified) to estimate prevalence of eligibility and common failure reasons. Where EHR prescreening will be used, validate that query logic doesn’t systematically miss language groups, older adults, or patients treated outside flagship sites. Build a prescreening specification and fairness check into the feasibility pack and keep it version-controlled for inspection.

Procedure and infrastructure readiness. Feasibility must confirm capacity and standards for procedures that are critical to quality (CtQ): imaging sequences, central reading prerequisites, ECG/QTc monitoring capabilities, pharmacy sterile prep, infusion chairs, emergency coverage, and availability of specialty labs (genotyping, minimal residual disease, viral load). For decentralizable tasks (e.g., ePRO, home health, local labs), verify that vendors operate in the target countries, that chain-of-custody and calibration are validated, and that sites are willing to use them.

Regulatory and ethics pathways by region. Even if the trial will be managed centrally, country-level requirements affect feasibility: import licenses for controlled substances, radiation safety approvals, device notifications, or data-hosting restrictions. Early conversations with regional experts reduce amendment churn later and ensure the protocol cites applicable policies in language coherent to reviewers at the FDA and EMA while remaining understandable under PMDA/TGA practices.

Comparator sourcing and SoC variability. If the control arm uses an active comparator, confirm formulary access, tender timelines, and legal pathways for import or named-patient supply. Document how SoC differs across regions (dosing, concomitant meds) and whether those differences threaten randomization, blinding, or endpoint timing. Where SoC heterogeneity is material, consider stratification by region or enrichment strategies rather than over-restrictive exclusions.

Participant burden and equity reality checks. Evaluate time and travel burden against the protocol’s visit cadence and procedure durations. Ask sites what would improve access (evening or weekend visits, childcare stipends, home phlebotomy). These inputs should drive windows, substitution rules, and decentralized elements in the Schedule of Assessments. Ethics committees expect proportionate burden and equitable access; feasibility data provide the evidence base.

Country, Site, and Patient Feasibility: Signals That Reshape Design

Country selection is a scientific decision—use data. Start with an eligibility heat map by country: estimated eligible prevalence, typical SoC, diagnostic latency, language coverage needs, and known regulatory timelines. Add operational factors: central lab footprint, imaging network capacity, import/export constraints, and historical site performance on similar indications. Choose fewer, stronger countries rather than a diffuse footprint that dilutes oversight and complicates logistics.

Site feasibility should go beyond survey checkboxes. Require evidence: prior enrollment curves, percentage on-time primary endpoint assessments, ePRO completion rates, audit history, turnover among coordinators, and pharmacy capabilities. For device or infusion trials, verify mock runs (e.g., sham setups, sterile prep timing). Ask for proof of patient sources: clinic volumes, referral agreements, and real prescreening logs from recent studies. Record all claims and corroborating documents in a Site Feasibility Dossier—a frequent pull during inspections.

Feasibility inputs that typically change protocols.

Eligibility thresholds that are too narrow for the patient pool (e.g., overly tight lab cut-offs); broaden with monitoring rather than exclusion when safe.
Visit windows that clash with imaging or lab turnaround times; widen or add substitution windows with home health support.
PK sampling density that clinics cannot operationalize; refine to rich + sparse hybrids that still answer the PK question.
Blinding risks from uniquely available comparators in certain countries; adjust supply and packaging or select alternative geographies.
Language coverage gaps; budget and plan for translations and cognitive debriefs before first-patient-in.

Patient voice belongs in feasibility. Convene advisory boards or interviews with patient organizations to test burden, consent clarity, and acceptability of procedures (e.g., lumbar puncture, frequent biopsies). These insights sharpen consent language, PRO selection, and compensation frameworks. They also reduce mid-study amendments by surfacing barriers early—aligning with the participant-focused ethos emphasized by WHO and consistent with ICH quality-by-design.

Data protection and technology readiness. Where eConsent, ePRO/eCOA, telemedicine, or wearables are proposed, confirm device availability, OS version support, offline capture capability, and data residency rules. Ensure privacy artifacts meet HIPAA (U.S.) and GDPR/UK-GDPR expectations (EU/UK). If data must be hosted in-region, choose vendors accordingly and reflect restrictions in the Data Management Plan and protocol privacy statements.

Controlled substances and special permits. Some investigational products require narcotics licenses, radioisotope permits, or biologic import clearances. Determine lead times and renewals during feasibility; if approvals exceed your activation timelines, reconsider countries or plan staggered activations. Mirror these realities in the critical path and contract terms to avoid avoidable delays.

Equity and fair selection. Use feasibility to identify barriers that might exclude underserved groups (transport deserts, limited internet access, language minorities). Counter with concrete accommodations—travel vouchers, device provision, interpreter availability—and encode them in the protocol and budget rather than leaving them to site discretion.

Operational Modeling That Drives Design: Enrollment, Supply, and Budget Inputs

Model enrollment from the ground up. Move beyond generic “X participants/site/month” guesses. Build a simple, transparent model: (1) Eligible prevalence per site derived from chart reviews or registry counts; (2) Approach rate (proportion of eligibles actually approached); (3) Consent rate; (4) Screen failure rate by criterion; (5) Randomization rate; and (6) Attrition. Express each as a range informed by feasibility inputs. Use these to produce median and pessimistic enrollment curves; power and timeline decisions should consider both.

Stress-test critical assumptions. Ask: What if diagnostic backlogs extend by four weeks? What if the biomarker prevalence is 10% lower than expected? What if ePRO completion is 75% without device provision but 90% with it? Model how these shifts affect timelines, cost, and statistical information (events accrued, evaluable primary timepoints). If minor design tweaks (wider windows, home visits, extra sites) neutralize the risks, bake them into the protocol up front.

Drug and device supply modeling. Unequal allocation, variable block sizes, re-supply lead times, cold-chain constraints, and shelf-life all interact with feasibility. Forecast depot and site inventory under your randomization plan; simulate “burn-down” by region to prevent stock-outs that could hint arm identity. If home delivery is planned, confirm courier networks, temperature monitors, and returns workflows. Reflect these dependencies in the protocol’s blinding and accountability language and in pharmacy manuals.

Central lab and imaging capacity. Capacity failures quickly become protocol deviations. Use feasibility to set realistic scan intervals and lab turnaround expectations. If your primary endpoint depends on adjudicated imaging, include read throughput assumptions (cases per reader per week), queue clearing before interim analyses, and contingency plans for site outages. Translate those assumptions into the Schedule of Assessments and endpoint definitions.

Budget and contracts are feasibility levers, not afterthoughts. Sites cannot deliver intensive procedures on goodwill alone. Price visit complexity (chair time, sedation, post-procedure monitoring), decentralized options (home health, device shipping), translations, and interpreter services. Include activation milestones and performance incentives aligned to quality metrics (on-time primary assessments, ePRO completion) rather than raw enrollment alone. This alignment improves execution quality and stands up to audits.

Risk assessment and Quality Tolerance Limits (QTLs). Convert feasibility findings into CtQ factors and QTLs: on-time primary endpoint rate, imaging within window, ePRO completion, and consent process adherence. Pre-define triggers for corrective actions (extra clinic hours, home visits, additional scanners) and document them in the Risk Management Plan. Regulators from the FDA and EMA increasingly expect this line of sight from feasibility → risk controls → monitoring.

Feasibility and estimands—keep the logic tight. If feasibility indicates frequent rescue medication or treatment switching in certain regions, concede that in your estimand: adopt a treatment-policy strategy and build analytic capture (rescue dates, switching reasons) rather than excluding high-need patients. Conversely, if assessments are fragile post-discontinuation, a while-on-treatment strategy may be more credible—again, informed by feasibility realities.

Plan for interim looks and adaptations realistically. If group-sequential or adaptive features are contemplated, ensure event accrual and information-time estimates reflect feasibility. Slow imaging or adjudication can distort information fractions; schedule queue clearing and reader capacity expansions ahead of interims and reference those operational safeguards in the protocol and charters.

Inspection-Ready Evidence: Feasibility Files, Decision Logs, and a Practical Checklist

Make feasibility auditable. Authorities and ethics committees do not require perfection, but they expect traceability: what you assumed, what you learned, and how the protocol changed. Maintain an indexed Feasibility Evidence Pack in the Trial Master File (TMF): epidemiology summaries; SoC maps; country checklists (import, data residency, radiation/device requirements); site dossiers; technology readiness (eConsent, eCOA, tele-visit, wearable specs); vendor coverage; comparator sourcing letters; and patient-advisory inputs. Version-control updates after pilot site visits or first-in-country activations.

Decision memos that connect dots. For every material protocol choice—eligibility thresholds, windows, imaging intervals, decentralized options—file a one-page feasibility rationale memo with the question, evidence, alternatives considered, and the decision. Cross-reference changes in the protocol, SAP, data-collection tools, and training plans. This is one of the fastest ways to answer inspector questions at the FDA, EMA, PMDA, and TGA.

Training and enablement derived from feasibility. Use findings to build site job aids (windowing quick cards, PK timing checklists), pharmacy manuals (cold chain, double-dummy assembly), and imaging acquisition guides. For decentralized elements, produce home-health kits with step-by-step instructions and timestamp capture, aligned with the protocol. Track completion and competency—inspectors often reconcile training rosters against who actually performed the procedures.

Monitoring signals keyed to feasibility risks. Centralized monitoring should track the very CtQ factors feasibility flagged: on-time primary assessments, imaging interval adherence, ePRO completion, kit stock-outs, and import-permit expiries. Set KRIs (key risk indicators) and QTLs with clear escalation paths. When thresholds are breached, the feasibility-informed mitigations (e.g., extra scanning slots, weekend clinics, device replacements) should already be approved and budgeted.

Common feasibility pitfalls—and how to prevent them.

Over-optimistic enrollment based on generic past performance: replace with site-specific eligible prevalence and approach/consent rates.
Unfunded burdens (e.g., frequent biopsies without reimbursement): align budget to procedure intensity and participant accommodations.
Comparator procurement risks: secure sourcing MoUs and shelf-life plans; adjust country mix if tenders are slow.
Technology gaps (eCOA not supported on common devices): validate device matrices and provide loaners where needed.
Language and literacy blind spots: complete translations and cognitive debriefs before site activation; provide interpreter access.
Blinding leakage via supply patterns: model kit burn-down and depot resupply; standardize pack appearance and courier docs.

Feasibility-to-protocol checklist (actionable excerpt).

Condition map complete (epidemiology, SoC, diagnostic latency) for each planned country; protocol windows match realities.
Eligibility tested on historical cohorts; top screen-failure reasons quantified; thresholds adjusted or mitigated.
Country/site dossiers evidence capacity: imaging, labs, pharmacy, ICU coverage, home health; comparator access confirmed.
Enrollment model documented (eligible → approached → consented → randomized → retained), with median/pessimistic curves.
Decentralized options validated (eConsent/eCOA/telehealth/wearables); privacy artifacts align with GDPR/HIPAA/UK-GDPR.
Supply model (randomization, shelf-life, cold chain, home shipments) integrated into blinding/accountability language.
QTLs derived from feasibility (on-time primary, imaging window, ePRO completion) and linked to predefined mitigations.
Patient-advisory inputs addressed (burden, clarity, acceptability); compensation/reimbursement proportional and ethics-approved.
Feasibility rationale memos filed; protocol/SAP/SoA updated coherently; training and system configurations reflect decisions.
Global coherence maintained with expectations recognizable to
ICH,

FDA,

EMA,

PMDA,

TGA,

and the WHO.

Bottom line. Feasibility is not a hurdle; it is the design engine. When you ground objectives, endpoints, and logistics in what patients, sites, and systems can truly deliver—and you file the evidence—your protocol becomes both ethical and executable, earning confidence from investigators and reviewers across the U.S., EU/UK, Japan, and Australia.